Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

Pfizer (PFE) stock in focus as its hemophilia drug Hympavzi succeeds in a Phase 3 trial. Read more here.

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

As a mom to a child withhemophilia, stepping away from sports seemed to be the only way to keep him protected from a life-threatening bleed.

You must have noticed that when you get injured, your blood turns to a gel, forming a blood clot. This mess your body is healing well. However, if you have haemophilia B, your blood won’t be able to ...

Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX va ...

The FDA has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or hemophilia B.

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic condition do not produce sufficient clotting factors, which can cause ...

What we know about the apparent bruise on Trump's hand Photographs have revealed discoloration on the back of the president's right hand.